Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
RIGL's Cash to Debt is ranked higher than
99% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.35 vs. RIGL: No Debt )
Ranked among companies with meaningful Cash to Debt only.
RIGL' s 10-Year Cash to Debt Range
Min: 4.48  Med: 63.90 Max: No Debt
Current: No Debt
Equity to Asset 0.68
RIGL's Equity to Asset is ranked higher than
59% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. RIGL: 0.68 )
Ranked among companies with meaningful Equity to Asset only.
RIGL' s 10-Year Equity to Asset Range
Min: 0.43  Med: 0.76 Max: 0.94
Current: 0.68
0.43
0.94
Interest Coverage No Debt
RIGL's Interest Coverage is ranked higher than
97% of the 390 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2854.00 vs. RIGL: No Debt )
Ranked among companies with meaningful Interest Coverage only.
RIGL' s 10-Year Interest Coverage Range
Min: 388.1  Med: 10000.00 Max: 9999.99
Current: No Debt
388.1
9999.99
F-Score: 3
Z-Score: -6.48
M-Score: -3.28
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -484.39
RIGL's Operating margin (%) is ranked lower than
94% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.92 vs. RIGL: -484.39 )
Ranked among companies with meaningful Operating margin (%) only.
RIGL' s 10-Year Operating margin (%) Range
Min: -14938.27  Med: -369.31 Max: 28.25
Current: -484.39
-14938.27
28.25
Net-margin (%) -482.44
RIGL's Net-margin (%) is ranked lower than
95% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.96 vs. RIGL: -482.44 )
Ranked among companies with meaningful Net-margin (%) only.
RIGL' s 10-Year Net-margin (%) Range
Min: -14872.93  Med: -372.65 Max: 30.31
Current: -482.44
-14872.93
30.31
ROE (%) -57.57
RIGL's ROE (%) is ranked lower than
88% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.43 vs. RIGL: -57.57 )
Ranked among companies with meaningful ROE (%) only.
RIGL' s 10-Year ROE (%) Range
Min: -142.64  Med: -61.08 Max: 27.46
Current: -57.57
-142.64
27.46
ROA (%) -46.27
RIGL's ROA (%) is ranked lower than
91% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. RIGL: -46.27 )
Ranked among companies with meaningful ROA (%) only.
RIGL' s 10-Year ROA (%) Range
Min: -101.94  Med: -47.82 Max: 23.14
Current: -46.27
-101.94
23.14
ROC (Joel Greenblatt) (%) -2973.30
RIGL's ROC (Joel Greenblatt) (%) is ranked lower than
94% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.24 vs. RIGL: -2973.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RIGL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4317.77  Med: -1731.87 Max: 1113
Current: -2973.3
-4317.77
1113
Revenue Growth (3Y)(%) 4.00
RIGL's Revenue Growth (3Y)(%) is ranked lower than
58% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. RIGL: 4.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RIGL' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -52.10 Max: 75.5
Current: 4
0
75.5
EBITDA Growth (3Y)(%) -8.80
RIGL's EBITDA Growth (3Y)(%) is ranked lower than
70% of the 494 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. RIGL: -8.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RIGL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -47.1  Med: -21.70 Max: 23.2
Current: -8.8
-47.1
23.2
EPS Growth (3Y)(%) -8.60
RIGL's EPS Growth (3Y)(%) is ranked lower than
67% of the 455 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. RIGL: -8.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RIGL' s 10-Year EPS Growth (3Y)(%) Range
Min: -56.5  Med: -21.50 Max: 21.8
Current: -8.6
-56.5
21.8
» RIGL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

RIGL Guru Trades in Q3 2014

Jim Simons 589,326 sh (+39.90%)
Chuck Royce 215,392 sh (unchged)
Paul Tudor Jones Sold Out
Charles Brandes Sold Out
» More
Q4 2014

RIGL Guru Trades in Q4 2014

Chuck Royce 215,392 sh (unchged)
Jim Simons 516,726 sh (-12.32%)
» More
Q1 2015

RIGL Guru Trades in Q1 2015

Paul Tudor Jones 13,814 sh (New)
Charles Brandes 44,700 sh (New)
Chuck Royce Sold Out
Jim Simons 100,900 sh (-80.47%)
» More
Q2 2015

RIGL Guru Trades in Q2 2015

Jim Simons 254,000 sh (+151.73%)
Paul Tudor Jones 18,713 sh (+35.46%)
Charles Brandes 44,700 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with RIGL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.61
RIGL's P/B is ranked higher than
57% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. RIGL: 2.61 )
Ranked among companies with meaningful P/B only.
RIGL' s 10-Year P/B Range
Min: 1.02  Med: 2.59 Max: 12.78
Current: 2.61
1.02
12.78
P/S 17.65
RIGL's P/S is ranked lower than
90% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.08 vs. RIGL: 17.65 )
Ranked among companies with meaningful P/S only.
RIGL' s 10-Year P/S Range
Min: 2.8  Med: 36.96 Max: 979
Current: 17.65
2.8
979
Current Ratio 4.26
RIGL's Current Ratio is ranked higher than
74% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. RIGL: 4.26 )
Ranked among companies with meaningful Current Ratio only.
RIGL' s 10-Year Current Ratio Range
Min: 1.84  Med: 8.70 Max: 36.3
Current: 4.26
1.84
36.3
Quick Ratio 4.26
RIGL's Quick Ratio is ranked higher than
78% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. RIGL: 4.26 )
Ranked among companies with meaningful Quick Ratio only.
RIGL' s 10-Year Quick Ratio Range
Min: 1.84  Med: 8.70 Max: 36.3
Current: 4.26
1.84
36.3
Days Sales Outstanding 8.18
RIGL's Days Sales Outstanding is ranked higher than
94% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.80 vs. RIGL: 8.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
RIGL' s 10-Year Days Sales Outstanding Range
Min: 12.04  Med: 34.75 Max: 293.53
Current: 8.18
12.04
293.53

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.73
RIGL's Price/Net Cash is ranked higher than
87% of the 175 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.86 vs. RIGL: 2.73 )
Ranked among companies with meaningful Price/Net Cash only.
RIGL' s 10-Year Price/Net Cash Range
Min: 1.2  Med: 3.55 Max: 15.44
Current: 2.73
1.2
15.44
Price/Net Current Asset Value 2.68
RIGL's Price/Net Current Asset Value is ranked higher than
83% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.25 vs. RIGL: 2.68 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
RIGL' s 10-Year Price/Net Current Asset Value Range
Min: 1.2  Med: 3.27 Max: 13.37
Current: 2.68
1.2
13.37
Price/Tangible Book 2.61
RIGL's Price/Tangible Book is ranked higher than
62% of the 590 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. RIGL: 2.61 )
Ranked among companies with meaningful Price/Tangible Book only.
RIGL' s 10-Year Price/Tangible Book Range
Min: 1.16  Med: 2.92 Max: 11.65
Current: 2.61
1.16
11.65
Price/Median PS Value 0.48
RIGL's Price/Median PS Value is ranked higher than
93% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.26 vs. RIGL: 0.48 )
Ranked among companies with meaningful Price/Median PS Value only.
RIGL' s 10-Year Price/Median PS Value Range
Min: 0.04  Med: 0.75 Max: 25.7
Current: 0.48
0.04
25.7
Earnings Yield (Greenblatt) (%) -62.04
RIGL's Earnings Yield (Greenblatt) (%) is ranked lower than
98% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. RIGL: -62.04 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RIGL' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -62.04  Med: 14.50 Max: 6128.3
Current: -62.04
-62.04
6128.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:RI2A.Germany,
Rigel Pharmaceuticals Inc was incorporated in the state of Delaware on June 14, 1996. The Company is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. The Companys pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. The Company currently has five product candidates in development: fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor entering in Phase 3 clinical trials for immune thrombocytopenic purpura (ITP) and a Phase 2 clinical trial for immunoglobulin A nephropathy (IgAN) in the first half of 2014; R348, a topical JAK/SYK inhibitor currently in Phase 2 clinical trials for dry eye; R118, an adenosine monophosphate (AMP)-activated protein kinase (AMPK) activator entering Phase 1 in the first half of 2014; and two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo, respectively. The Company is conducting proprietary research in the broad disease areas of inflammation/immunology and muscle wasting/muscle endurance. The Companys major competitors include fully integrated pharmaceutical companies that have extensive drug discovery efforts and are developing novel small molecule pharmaceuticals. The Company is subject to extensive regulation by numerous governmental authorities in the United States and other countries, including the FDA under the Federal Food, Drug and Cosmetic Act.
» More Articles for RIGL

Headlines

Articles On GuruFocus.com
Biocept (BIOC) Soars on Liquid Biopsy Appreciation, Rigel Pharmaceuticals (RIGL) Mega-deal with Bris Feb 23 2015 
Rigel Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 01 2011 

More From Other Websites
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Aug 18 2015
RIGEL PHARMACEUTICALS INC Financials Aug 11 2015
10-Q for Rigel Pharmaceuticals, Inc. Aug 06 2015
Edited Transcript of RIGL earnings conference call or presentation 4-Aug-15 8:30pm GMT Aug 05 2015
Rigel reports 2Q loss Aug 04 2015
Rigel reports 2Q loss Aug 04 2015
Rigel Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today Aug 04 2015
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 04 2015
Rigel Announces Second Quarter 2015 Financial Results Aug 04 2015
Q2 2015 Rigel Pharmaceuticals Inc Earnings Release - After Market Close Aug 04 2015
Rigel Announces Conference Call and Webcast to Report Second Quarter 2015 Financial Results Jul 28 2015
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Jul 01 2015
Rigel Welcomes Keith A. Katkin to Board of Directors Jun 30 2015
Rigel to Present at Jefferies 2015 Global Healthcare Conference May 28 2015
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 15 2015
Rigel reports 1Q loss May 07 2015
Rigel reports 1Q loss May 07 2015
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 07 2015
RIGEL PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report May 07 2015
Rigel Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today May 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK